Stay updated with breaking news from Compassionate Access Authorization. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ABIONYX Pharma announced that the company has been granted a new Compassionate Access Authorization in Europe for CER-001 in the rare, untreated kidney disease LCAT Deficiency. This is the fourth...
2022 revenues: €5.3 million Reduction of the annual operating loss Cash position of €4 million as of December 31, 2022 Continued clinical development following the succession
Continued focus of the Services activity on the Biotech's preclinical studies in ophthalmology Determination of the strategic axes of clinical development in ophthalmology is ongoing
Focus of the Services activityon the Biotech's preclinical studies in ophthalmology Determination of the strategic axes of clinical development in ophthalmology Cash position of €5.9
Cash position of €7.9 million as of December 31, 2021 Positive clinical results throughout the year Strategic partnership with IRIS Pharma to accelerate development in ophthalmology Regulatory